Market Overview

2020 Outlook on Acute On Chronic Liver Failure - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Share:

The "Acute On Chronic Liver Failure (ACLF) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical, and forecasted Acute on Chronic Liver Failure epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acute on Chronic Liver Failure: Understanding

The 's Acute on Chronic Liver Failure epidemiology report gives a thorough understanding of the Acute on Chronic Liver Failure by including details such as disease definition, types, clinical characteristics, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Acute on Chronic Liver Failure in Europe and Asia. Moreover, the report covers the detailed information of the Acute on Chronic Liver Failure epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective:

This section encompassing Acute on Chronic Liver Failure epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The Acute on Chronic Liver Failure epidemiology data is studied through all possible division to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The Acute on Chronic Liver Failure epidemiology covered in the report provides historical as well as forecasted Acute on Chronic Liver Failure epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Report Highlights:

  • 11-year Forecast of Acute on Chronic Liver Failure Epidemiology
  • 7MM Coverage
  • Cases of Acute-on-chronic liver failure (ACLF)
  • Cases of Acute on Chronic Liver Failure by Grades
  • Organ failures associated with Acute on Chronic Liver Failure
  • Potential precipitating events of Acute on Chronic Liver Failure

Key Questions Answered:

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Acute on Chronic Liver Failure?
  • What are the key findings pertaining to the Acute on Chronic Liver Failure epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Acute on Chronic Liver Failure across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the currently available treatments of Acute on Chronic Liver Failure?

Reasons to buy:

The Acute on Chronic Liver Failure Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Acute on Chronic Liver Failure market.
  • Quantify patient populations in the global Acute on Chronic Liver Failure market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acute on Chronic Liver Failure therapeutics in each of the markets covered
  • Understand the magnitude of Acute on Chronic Liver Failure population by its epidemiology
  • The Acute on Chronic Liver Failure Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Topics Covered:

1 Executive Summary of Acute on Chronic Liver Failure

2 ACLF Epidemiology Overview at a Glance

2.1 Patient Share (%) Distribution of ACLF in 2017

2.2 Patient Share (%) Distribution of ACLF in 2030

3 Disease Background and Overview

3.1 Introduction

3.2 Heterogeneity of definitions

3.3 Types of ACLF

3.4 Clinical characteristics and pathophysiology

3.5 Diagnosis of ACLF

3.6 ACLF biomarkers

4 Country-wise Epidemiology of Acute-on-Chronic Liver Failure (ACLF)

4.1 Assumptions and Rationale: 7MM

5 Epidemiology and Patient Population

5.1 Key Findings

5.2 United States

5.3 Germany

5.4 France

5.5 Italy

5.6 Spain

5.7 United Kingdom

5.8 Japan

6 Treatment

6.1 Guidelines

6.1.1 APASL

6.1.2 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

6.2 Case Study

6.2.1 Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis

6.3 Patient Journey

7 Appendix

7.1 Report Methodology

8 Publisher Capabilities

9 Disclaimer

10 About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/lae1nl

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com